

1654
Taw

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
16153

In Re Application Of: *Koch Jeffrey Barnham, et al.*

MAR 27 2006

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/031,478	July 29, 2002	Andrew D. Kosar	23389	1654	8704

Title: **BETA-AMYLOID PEPTIDE INHIBITORS**

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
 16153

In Re Application of: **Kevin Jeffrey Barnham, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/031,478	July 29, 2002	Andrew D. Kosar	23389	1654	8704

Title: **BETA-AMYLOID PEPTIDE INHIBITORS**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
 - Charge the amount of _____
 - Credit any overpayment.
 - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(e)] on

March 23, 2006


(Date)

Signature of Person Mailing Correspondence

Edward W. Grolz

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.



Dated: March 23, 2006

Edward W. Grolz

Registration No. 33,705

Scully, Scott, Murphy & Presser, P.C.
 400 Garden City Plaza-STE 300
 Garden City, New York 11530
 (516) 742-4343

cc: EWG:ab



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kevin Jeffrey Barnham, et al. **Examiner:** Andrew D. Kosar
Serial No.: 10/031,478 **Art Unit:** 1654
Filed: July 29, 2002 **Docket:** 16153
For: BETA-AMYLOID PEPTIDE
INHIBITORS **Dated:** March 23, 2006

Confirmation No. 8704

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: March 23, 2006


Edward W. Grolz

1. International Patent Publication No. WO 97/21431, published June 19, 1997;
2. International Patent Publication No. WO 00/09111, published February 24, 2000;
3. Caughey, W. S. et al., "Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines", *Proc. Natl. Acad. Sci. USA*, 95: 12117-12122 (1998), XP000904870;
4. Liu, Su-Ting et al., "Histidine-13 Is a Crucial Residue in the Zinc Ion-Induced Aggregation of the A β Peptide of Alzheimer's Disease", *Biochemistry*, 38(29): 9373-9378 (1999), XP002266540;
5. Howlett, D. et al., "Hemin and related porphyrins inhibit β -amyloid aggregation", *FEBS Letters*, 417: 249-251 (1997), XP000891946;
6. International Patent Publication No. WO 99/34807, published July 15, 1999;
7. Gray, D. N. et al., "Resolubilization of Alzheimer and APP transgenic beta amyloid plaque by copper chelators", 28th Annual Meeting of the Society for Neuroscience, Part 1, November 7-12, 1998, Society for Neuroscience, Abstract, Number 282.13; and
8. Cherny, R. A. et al., "Aqueous Dissolution of Alzheimer's Disease A β Amyloid Deposits by Biometal Depletion", *The Journal of Biological Chemistry*, 274(33): 23223-23228 (1999).

Reference numbers 1-5 were cited in a Supplementary Partial European Search Report, dated February 13, 2004. Applicants are submitting copies of the above-cited references, together with a copy of the Search Report. The relevance of the above-identified references has been described in the Search Report.


Reference numbers 6-8 were cited in an Examination Report dated December 6, 2005 received from the European Patent Office. Applicants are submitting a copy of the above-cited references, together with a copy of the Examination Report. The relevance of the above-identified references has been described in the Examination Report. Atwood, et al., *Journal of*

Biological Chemistry, 273(21): 12817-12826 (1998) was previously submitted in applicant's Information Disclosure Statement dated July 23, 2002.

Applicants further respectfully submit that reference numbers 1-5 were also cited in an Examination Report dated December 9, 2004 from the European Patent Office. Applicants are submitting a copy of the Examination Report. The relevance of the above-identified references has been described in the Examination Report. International Patent Publication No. WO 98/44955, published October 15, 1998 and International Patent Publication No. WO 95/12815, published May 11, 1995 were previously submitted in applicant's Information Disclosure Statement dated July 23, 2002

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Edward W. Grolz
Registration No. 33,705

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343
EWG:ab



Form PTO-1449 (REV. 10-20-00) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Atty. Docket No. 16153	Serial No. 10/031,478
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		Applicants Kevin Jeffrey Barnham, et al.	
		Filing Date July 29, 2002	Group 1654

U.S. PATENT DOCUMENTS

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)

		Foreign Document Number	Date	Country	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
1.	WO 97/21431	6/19/1997	PCT					
2.	WO 00/09111	2/24/2000	PCT					
6.	WO 99/34807	7/15/1999	PCT					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

3.	Caughey, W. S. et al., "Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines", <i>Proc. Natl. Acad. Sci. USA</i> , 95: 12117-12122 (1998), XP000904870
4.	Liu, Su-Ting et al., "Histidine-13 Is a Crucial Residue in the Zinc Ion-Induced Aggregation of the A β Peptide of Alzheimer's Disease", <i>Biochemistry</i> , 38(29): 9373-9378 (1999), XP002266540
5.	Howlett, D. et al., "Hemin and related porphyrins inhibit β -amyloid aggregation", <i>FEBS Letters</i> , 417: 249-251 (1997), XP000891946
7.	Gray, D. N. et al., "Resolubilization of Alzheimer and APP transgenic beta amyloid plaque by copper chelators", 28 th Annual Meeting of the Society for Neuroscience, Part 1, November 7-12, 1998, Society for Neuroscience, Abstract, Number 282.13
8.	Cherny, R. A. et al., "Aqueous Dissolution of Alzheimer's Disease A β Amyloid Deposits by Biometal Depletion", <i>The Journal of Biological Chemistry</i> , 274(33): 23223-23228 (1999)

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.